Drug intelligence / Profile preview

APR006

Development stage: Unknown
Lead developer: Apros Therapeutics
Modality: Small Molecules

Overview

**APR006** is an investigational Apros Therapeutics vaccine-adjuvant candidate comprising a small-molecule **Toll-like receptor 7** agonist formulated with aluminum hydroxide. By activating TLR7-mediated innate immune signaling, the formulation is intended to enhance immune responses to a co-administered vaccine antigen. Apros Therapeutics describes APR006 as an early-stage program with GMP material available for collaboration.

Targets

TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on APR006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APR006.

Explore the full profile